<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20140527017880N7</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-11-08</date_registration>
      <primary_sponsor>Kermanshah University of Medical Sciences</primary_sponsor>
      <public_title>Determining the effect of low-level laser therapy on reducing the injection pain</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of low-level laser therapy on pain reduction of anterior maxillary infiltration injection</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-07-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>84</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/33332</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Crossover, Purpose: Treatment, Randomization description: Randomization is a simple method meaning that the selected units have the equal chance of been chosen. Random unit is of individual type and choosing and random instruments are selected envelopes for which the selection process can be carried out by lottery or by person. In this way, the patients are provided with two sets of envelopes. One set includes 84 envelopes: 42 A and 42 B (A: right and B: left) and the other set includes 84 envelopes: 42 C and 42 D (C: intervention side and D: Control side) and then each patient by choosing two envelopes from each set will determine the intervention or control side in the first run and at the next run the reverse is carried out, Blinding description: First, the patient chooses one of the C or D envelopes (C: laser radiation with power of 100 mw, D: laser radiation with power of 0 mw as placebo), then the first executor adjusts the laser device according to the patient-selected envelope, and eventually the second executor adjusts the low-level laser without noticing the patient's choice and immediately does the injection. Then, the patient determines the pain intensity by the use of the visual analog index, and then the analyst analyzes the information without knowing the codes. Blinding is done only by one of the researchers. Therefore, the patient, the injector and the analyst won't find out whether the laser has been radiated or not.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Local anesthesia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: first laser with power of 100 mw is radiated. The characteristics of the laser are as follow: low-level laser from Quick Laser with simultaneous radiations (810 and 980 nm), power of 12 w, manufactured by England Quick Laser Company, with the energy of 4 j/cm2  and cross section of 225 mm2 that is applied to the mucous membrane in a vertical form throughout the method of contact with no pressure texture in 90 seconds by a dentist. Then immediately, a 4% lidocaine carpool (epinephrine 1:100000, Iran Daroo Pakhsh) will be injected. All the injections will be carried out under the same circumstances in the depth of vestibule and adjacent to the root of maxillary’s central tooth by a dentist (The bull of the needle’s point should be toward the bone, the needle should be short 27 and the depth of needle penetration should be 2-4 mm and the time of carpool evacuation should be 1 minute). Intervention 2: Control group: first laser with power of 0 mw is radiated as plascebo. The characteristics of the laser are as follow: low-level laser from Quick Laser with simultaneous radiations (810 and 980 nm), power of 12 w, manufactured by England Quick Laser Company, with the energy of 4 j/cm2  and cross section of 225 mm2 that is applied to the mucous membrane in a vertical form throughout the method of contact with no pressure texture in 90 seconds by a dentist. Then immediately, a 4% lidocaine carpool (epinephrine 1:100000, Iran Daroo Pakhsh) will be injected. All the injections will be carried out under the same circumstances in the depth of vestibule and adjacent to the root of maxillary’s central tooth by a dentist (The bull of the needle’s point should be toward the bone, the needle should be short 27 and the depth of needle penetration should be 2-4 mm and the time of carpool evacuation should be 1 minute).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hosna Bahrami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Across from the post office, Shora st, Dr Shariati st</address>
        <city>Kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6713954658</zip>
        <telephone>+98 83 3722 2400</telephone>
        <email>bahrami.h1994@gmail.com</email>
        <affiliation>Kermanshah University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Roohollah Sharifi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Across from the post office, Shora st, Dr Shariati st</address>
        <city>Kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6713954658</zip>
        <telephone>+98 83 3722 7151</telephone>
        <email>roholahsharifi@gmail.com</email>
        <affiliation>Kermanshah University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>General health
Absence of pathologic lesion at the injection site
Age range from 20 to 25 years
In need of restoration or root treatment</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>25 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Allergy to Lidocaine injectable drug
Use of any sedative and anti-depression drugs in two weeks period</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Y48.3</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Local anaesthetics</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: first laser with power of 100 mw is radiated. The characteristics of the laser are as follow: low-level laser from Quick Laser with simultaneous radiations (810 and 980 nm), power of 12 w, manufactured by England Quick Laser Company, with the energy of 4 j/cm2  and cross section of 225 mm2 that is applied to the mucous membrane in a vertical form throughout the method of contact with no pressure texture in 90 seconds by a dentist. Then immediately, a 4% lidocaine carpool (epinephrine 1:100000, Iran Daroo Pakhsh) will be injected. All the injections will be carried out under the same circumstances in the depth of vestibule and adjacent to the root of maxillary’s central tooth by a dentist (The bull of the needle’s point should be toward the bone, the needle should be short 27 and the depth of needle penetration should be 2-4 mm and the time of carpool evacuation should be 1 minute).</i_keyword>
      <i_keyword>Control group: first laser with power of 0 mw is radiated as plascebo. The characteristics of the laser are as follow: low-level laser from Quick Laser with simultaneous radiations (810 and 980 nm), power of 12 w, manufactured by England Quick Laser Company, with the energy of 4 j/cm2  and cross section of 225 mm2 that is applied to the mucous membrane in a vertical form throughout the method of contact with no pressure texture in 90 seconds by a dentist. Then immediately, a 4% lidocaine carpool (epinephrine 1:100000, Iran Daroo Pakhsh) will be injected. All the injections will be carried out under the same circumstances in the depth of vestibule and adjacent to the root of maxillary’s central tooth by a dentist (The bull of the needle’s point should be toward the bone, the needle should be short 27 and the depth of needle penetration should be 2-4 mm and the time of carpool evacuation should be 1 minute).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain intensity of infiltration injection. Timepoint: Immediately after injection. Method of measurement: Based on the Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kermanshah University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-08-15</approval_date>
        <contact_name>Ethics Committee of Kermanshah University of Medical Sciences</contact_name>
        <contact_address>Ethics Committee, Vice Chancellor for Research and Technology, Building No.2, Kermanshah University of Medical Sciences, Shahid Beheshti Boulverd Kermanshah Kermanshah Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
